Safe Results Of Biogen Idec Inc (NASDAQ:BIIB)’s Tecfidera, Endorse study
Written by Larissa Castillo on October 4, 2013
Tecfidera is the new multiple sclerosis drug introduced by Biogen Idec Inc (NASDAQ:BIIB). This drug has consistently maintained its effect of reducing disease bustle in patients over four years, presented by Endorse trial. Most noticeable thing is that no safety concerns came to forefront in patients. Vice President of Research and Development sector said that MS is a lifelong, unrelieved disease and doctors and patients should have a trust that they are adapting a persistent efficacy with a persistent safety measures. Analysts are expecting that this drug will definitely dominate the MS drug market as it already had sales of $192 million in the very first quarter.
The chairman of the department of neurology has stated that Endorse latest findings actually endorse those results that have been concluded previously and that data provides the major information to all doctors and patients. Biogen said that no risks of serious infections and cancer are being observed during drug usage. Moreover, liver problems and kidneys dysfunction problems are also not existed while usage.
Patients, who kept in control groups for the earlier two years, receive either Copaxone or placebo from the MS leader pharmaceutical industries. In Endorse trial when Tecfidera is being given to them then they showed the very similar response as the ones who receive that drug in their early years.
When compared with placebo, Tecfidera leads by 54 percent reduction in the risk of multiple sclerosis relapse. Despite that researchers are still observing the 1,738 patients with RRMS in Endorse trial. These under observation patients are receiving 240 milligrams of the new MS drug, three or four times a day.
Relapsing-remitting multiple sclerosis (RRMS) is known to be the most common type of disease and almost two million of people are suffering from that all around the world. That disease causes malfunctions in neurological function which is further followed by the periods of remission.